stockportfolio.pro
United Therapeutics Corporation (UTHR)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
United Therapeutics Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.60B | $1.73B | $1.63B | $1.45B | $1.48B | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B |
| Gross profit | $1.53B | $1.62B | $1.43B | $1.33B | $1.38B | $1.56B | $1.78B | $2.07B | $2.57B | $2.80B |
| Net income | $713.70M | $417.90M | $589.20M | $-104.50M | $0 | $475.80M | $727.30M | $984.80M | $1.20B | $1.33B |
| Net margin | 44.6% | 24.2% | 36.2% | -7.2% | 0.0% | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
Source: United Therapeutics Corporation SEC filings (10-K). 18 years of history available in the interactive view.
Explore 18 years of United Therapeutics Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track UTHR in your portfolio →
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
United Therapeutics Corporation — frequently asked questions
What is United Therapeutics Corporation's revenue?
United Therapeutics Corporation (UTHR) reported revenue of $3.18B for fiscal year 2025, up 10.6% from the prior year, according to its SEC filings.
Is United Therapeutics Corporation profitable?
Yes. UTHR earned net income of $1.33B in fiscal 2025, a net margin of 41.9%.
What is UTHR's P/E ratio?
United Therapeutics Corporation trades at a price-to-earnings ratio of about 20.0 based on the latest data in our nightly-refreshed cache.
How fast is United Therapeutics Corporation growing?
UTHR's revenue grew at roughly 16.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from United Therapeutics Corporation's official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.